{ "@context": "https://schema.org", "@graph": [ { "@type": "LegalCase", "@id": "case-9835", "postId": 9835, "name": "EyePoint, Inc.", "description": "Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In EyePoint To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in EyePoint between May 27, 2025 and August 14, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against EyePoint, Inc. (\u201cEyePoint\u201d or the \u201cCompany\u201d) (NASDAQ: EYPT) and reminds investors of the January 19, 2027 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) DURAVYU was less effective than Defendants had led investors to believe; (ii) accordingly, DURAVYU’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times. Lead Plaintiff Deadline: January 19, 2027 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). Or submit your information below to learn about your rights.", "identifier": "EYPT", "legal": { "court": "United States Federal District Court of Eastern District of New York", "jurisdiction": "Federal (United States), federal securities laws" }, "classPeriod": { "start": "05/27/2025", "end": "08/14/2026" }, "leadPlaintiffDeadline": "01/19/2027", "caseStatus": { "name": "", "slug": "" }, "practiceArea": { "name": "Securities Litigation", "slug": "securities-litigation" }, "url": "https://faruqilaw.com/case/eyepoint-inc/", "canonicalUrl": "https://faruqilaw.com/case/eyepoint-inc/", "datePublished": "2026-11-18T19:25:36+00:00", "dateModified": "2026-11-18T19:25:36+00:00", "associatedOrganization": { "@id": "case-9835-org" }, "legalService": { "@id": "case-9835-legalservice" }, "hasPart": [ { "@id": "case-9835-faq" }, { "@id": "case-9835-press-list" } ], "legalRepresentation": [ { "@id": "case-9835-attorney-516" }, { "@id": "case-9835-attorney-506" } ] }, { "@type": "Organization", "@id": "case-9835-org", "name": "EyePoint, Inc.", "identifier": "EYPT", "logo": "https://faruqilaw.com/wp-content/uploads/2025/05/logo.svg", "url": "https://eyepoint.bio/" }, { "@type": "LegalService", "@id": "case-9835-legalservice", "name": "Faruqi & Faruqi, LLP", "url": "https://faruqilaw.com/", "telephone": "+1-212-983-9330", "logo": "https://faruqilaw.com/wp-content/uploads/2025/05/logo.svg", "address": { "@type": "PostalAddress", "streetAddress": "685 3rd Ave 26th Floor", "addressLocality": "New York", "postalCode": "10017", "addressRegion": "NY", "addressCountry": "US" }, "sameAs": [ "https://faruqilaw.com/", "https://maps.google.com/?cid=3247549158190754383" ] }, { "@type": "Person", "@id": "case-9835-attorney-516", "name": "James M. Wilson, Jr.", "worksFor": { "@id": "case-9835-legalservice" } }, { "@type": "Person", "@id": "case-9835-attorney-506", "name": "Robert W. Killorin", "worksFor": { "@id": "case-9835-legalservice" } }, { "@type": "FAQPage", "@id": "case-9835-faq", "mainEntity": [ { "@type": "Question", "name": "What is the EyePoint securities class action about?", "acceptedAnswer": { "@type": "Answer", "text": "A securities class action has been filed in the U.S. District Court for the Eastern District of New York against EyePoint, Inc. (NASDAQ: EYPT) and certain defendants. The complaint alleges that Defendants made materially false and misleading statements about the company's drug candidate DURAVYU. These are allegations only, and they have not been proven in court." } }, { "@type": "Question", "name": "What does the lawsuit allege about DURAVYU?", "acceptedAnswer": { "@type": "Answer", "text": "The complaint alleges that DURAVYU was less effective than Defendants had led investors to believe. It further alleges that, as a result, DURAVYU's clinical, regulatory, and commercial prospects were overstated. Defendants' public statements were therefore allegedly materially false and misleading at all relevant times." } }, { "@type": "Question", "name": "What is the class period for the EyePoint (EYPT) lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "The class period runs from May 27, 2025 to August 14, 2026. Investors who purchased or otherwise acquired EyePoint securities during this window may be affected by the allegations. Whether any particular investor qualifies to participate depends on the court's rulings and the final class definition." } }, { "@type": "Question", "name": "What is the lead plaintiff deadline in the EyePoint class action?", "acceptedAnswer": { "@type": "Answer", "text": "The deadline to seek appointment as lead plaintiff is January 19, 2027. Investors who wish to ask the court to appoint them to this role must act by that date. Missing the deadline does not necessarily prevent an investor from remaining a member of the putative class, but it does mean they cannot seek the lead plaintiff role." } }, { "@type": "Question", "name": "Which court is handling the EyePoint securities class action?", "acceptedAnswer": { "@type": "Answer", "text": "The case is pending in the U.S. District Court for the Eastern District of New York. The court will oversee the proceedings, including the appointment of a lead plaintiff and any decisions about the claims. Case developments will depend on the court's schedule and rulings." } }, { "@type": "Question", "name": "What is a lead plaintiff in a securities class action?", "acceptedAnswer": { "@type": "Answer", "text": "A lead plaintiff is a investor, or group of investors, appointed by the court to represent the interests of the class and to oversee the litigation. The appointment is generally made after the filing deadline passes. Serving as lead plaintiff is not required to take part in any potential recovery as a class member." } }, { "@type": "Question", "name": "Who may be affected by the EyePoint (EYPT) class action?", "acceptedAnswer": { "@type": "Answer", "text": "Investors who purchased or otherwise acquired EyePoint securities between May 27, 2025 and August 14, 2026 may be affected by the allegations in the complaint. Individual circumstances vary, so investors with questions about their own situation may wish to consult a qualified securities attorney." } }, { "@type": "Question", "name": "Has the court decided whether EyePoint did anything wrong?", "acceptedAnswer": { "@type": "Answer", "text": "No. The claims in the complaint are allegations, and the court has not made findings against EyePoint or any other defendant. The outcome of the case will depend on the legal process, including any motions, evidence, and rulings." } }, { "@type": "Question", "name": "What should EyePoint investors do if they have questions about the lawsuit?", "acceptedAnswer": { "@type": "Answer", "text": "Investors who bought EyePoint (EYPT) securities during the class period may wish to review the complaint and the January 19, 2027 lead plaintiff deadline. They may also consider speaking with a qualified securities attorney about their rights and options. This page provides general information and is not legal advice." } } ] }, { "@type": "NewsArticle", "@id": "case-9835-press-1", "headline": "Stifel cuts EyePoint stock price target on trial setbacks", "url": "https://www.investing.com/news/analyst-ratings/stifel-cuts-eyepoint-stock-price-target-on-trial-setbacks-93CH-5025313", "datePublished": "2026-11-13" }, { "@type": "NewsArticle", "@id": "case-9835-press-2", "headline": "EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments", "url": "https://www.stocktitan.net/news/EYPT/eye-point-reports-third-quarter-2026-financial-results-and-provides-ceuvoeq6i501.html", "datePublished": "2026-11-12" }, { "@type": "NewsArticle", "@id": "case-9835-press-3", "headline": "EyePoint to halve workforce after experimental drug fails second late-stage trial", "url": "https://www.reuters.com/legal/litigation/eyepoint-cut-workforce-by-half-after-experimental-drug-fails-second-late-stage-2026-10-19/", "datePublished": "2026-10-19" }, { "@type": "NewsArticle", "@id": "case-9835-press-4", "headline": "EyePoint Drug Trial Flop Crashes Stock. Can a Strategy Shift Save It?", "url": "https://www.barrons.com/articles/eyepoint-stock-sinks-failed-drug-trial-7b65e1a4", "datePublished": "2026-10-19" }, { "@type": "NewsArticle", "@id": "case-9835-press-5", "headline": "EyePoint drops as TD Cowen becomes latest to downgrade on late-stage trial setback", "url": "https://seekingalpha.com/news/4639483-eyepoint-stock-drops-td-cowen-downgrades", "datePublished": "2026-09-02" }, { "@type": "NewsArticle", "@id": "case-9835-press-6", "headline": "EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu", "url": "https://www.fiercepharma.com/pharma/eyepoint-shares-plummet-amid-phase-3-stumble-amd-drug-device-combo-duravyu", "datePublished": "2026-08-17" }, { "@type": "NewsArticle", "@id": "case-9835-press-7", "headline": "EyePoint Stock Plummets on Mixed Primary Data From Blindness Drug Study", "url": "https://www.benzinga.com/trading-ideas/movers/26/08/61249866/eyepoint-stock-plummets-on-mixed-primary-data-from-blindness-drug-study", "datePublished": "2026-08-17" }, { "@type": "ItemList", "@id": "case-9835-press-list", "itemListElement": [ { "@type": "ListItem", "position": 1, "item": { "@id": "case-9835-press-1" } }, { "@type": "ListItem", "position": 2, "item": { "@id": "case-9835-press-2" } }, { "@type": "ListItem", "position": 3, "item": { "@id": "case-9835-press-3" } }, { "@type": "ListItem", "position": 4, "item": { "@id": "case-9835-press-4" } }, { "@type": "ListItem", "position": 5, "item": { "@id": "case-9835-press-5" } }, { "@type": "ListItem", "position": 6, "item": { "@id": "case-9835-press-6" } }, { "@type": "ListItem", "position": 7, "item": { "@id": "case-9835-press-7" } } ] } ] }

EyePoint, Inc.

EyePoint, Inc.

Join Action
Case Details
Ticker EYPT
Class Period 05/27/2025 - 08/14/2026
Lead Plaintiff Deadline 01/19/2027
Days Left to Seek Lead Plaintiff
61

If you are an EyePoint, Inc. investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In EyePoint To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in EyePoint between May 27, 2025 and August 14, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT) and reminds investors of the January 19, 2027 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) DURAVYU was less effective than Defendants had led investors to believe; (ii) accordingly, DURAVYU’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Lead Plaintiff Deadline: January 19, 2027

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). Or submit your information below to learn about your rights.

Join Action
EyePoint, Inc.
1
1
1
1

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Counsel
James M. Wilson, Jr.
jwilson@faruqilaw.com
Phone (212) 983-9330
Fax (212) 983-9331
Robert W. Killorin
rkillorin@faruqilaw.com
Phone (404) 847-0617
Fax (404) 506-9534
Office
Pennsylvania
1617 JFK Boulevard, Suite 1550 Philadelphia Pennsylvania 19103
Phone (215) 277-5770
Fax (215) 277-5771

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
Send Us a Message
New York
685 Third Avenue 26th Floor
New York New York 10017
(877) 247-4292 / (212) 983-9330
(212) 983-9331
Los Angeles
1901 Avenue of the Stars Suite 1060
Los Angeles California 90067
(424) 256-2884
(424) 256-2885
Atlanta
3565 Piedmont Road NE Building Four, Suite 380
Atlanta Georgia 30305
(404) 847-0617
(404) 506-9534
Philadelphia
1617 JFK Boulevard, Suite 1550 Philadelphia
Pennsylvania 19103
(215) 277-5770
(215) 277-5771